Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
- Author:
Lin-Run WANG
1
;
Ming-Zhu HUANG
;
Nong XU
;
Jian-Zhong SHENTU
;
Jian LIU
;
Jie CAI
Author Information
1. First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China. linrunw@yahoo.com.cn
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Aged;
Carcinoma, Non-Small-Cell Lung;
blood;
China;
Deoxycytidine;
administration & dosage;
analogs & derivatives;
blood;
pharmacokinetics;
Female;
Humans;
Male;
Middle Aged;
Time Factors
- From:
Journal of Zhejiang University. Science. B
2005;6(5):446-450
- CountryChina
- Language:English
-
Abstract:
To determine the pharmacokinetics of gemcitabine (2',2'-difluorodeoxycytidine) in Chinese non-small-cell lung cancer (NSCLC) patients. Six study subjects were administered gemcitabine at a fixed dose rate of 10 mg/m(2) per min (1200 mg/m(2), two hours infusion), and carboplatin and plasma gemcitabine concentrations were measured by ion-pair reversed-phase high-performance liquid chromatography (HPLC). 3P97 Pharmaceutical Kinetics Software was used for the calculation of pharmacokinetic parameters. The obtained mean parameters, elimination half life (t(1/2)) (10.67+/-3.38 min), area under the curve (AUC) (7.55+/-1.53 (microg x h)/ml), and clearance (CL) (3940.05+/-672.08 ml/min), were consistent with those reported in literature. The hematologic toxicology result showed that the regimen was effective on and tolerated by the patients.
